CA
CHRS icon

Clearstead Advisors’s Coherus Oncology CHRS Stock Holding History

Clearstead Advisors’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.17K Buy
836
+570
+214% +$931 ﹤0.01% 2648
2026
Q1 		$449 Sell
266
-3
-1% -$5 ﹤0.01% 2123
2025
Q4 		$382 Sell
269
-886
-77% -$1.29K ﹤0.01% 2339
2025
Q3 		$1.9K Sell
1,155
-625
-35% -$695 ﹤0.01% 2462
2025
Q2 		$1.3K Buy
+1,780
New +$1.54K ﹤0.01% 2399

Other funds holding CHRS

TGY2IT
Timothy G. Youngquist 2020 Irrevocable Trust Fort Myers, Florida $510M AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $157M AUM 60.08% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.15B AUM 13.14% 1-Year Est. Return

Clearstead Advisors's CHRS Position: Q2 2026 in Review

Clearstead Advisors increased its Coherus Oncology (CHRS) stake by 214% in Q2 2026, buying an estimated $931 and bringing the position to 836 shares worth $1.17K. The position accounts for ﹤0.01% of the portfolio, ranked #2648.

Clearstead Advisors first reported a position in CHRS in Q2 2025 and has held it in 5 quarters since. The position peaked at $1.9K in Q3 2025. 147 funds tracked by Wall St. Rank hold CHRS as of Q2 2026.

  • Clearstead Advisors held 836 shares of Coherus Oncology worth $1.17K as of Q2 2026.
  • Clearstead Advisors bought 570 Coherus Oncology shares in Q2 2026, an estimated $931.
  • Coherus Oncology made up ﹤0.01% of Clearstead Advisors's portfolio in Q2 2026, its #2648 holding.
  • Clearstead Advisors first reported a position in Coherus Oncology in Q2 2025 and has held it in 5 quarters since.
  • Clearstead Advisors's Coherus Oncology position peaked at $1.9K in Q3 2025.
  • 147 funds tracked by Wall St. Rank held Coherus Oncology as of Q2 2026.

Based on Clearstead Advisors's 13F filing for Q2 2026, filed 6 Aug 2026.